Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014.
Opneja A, Cioffi G, Alahmadi A, Jones N, Tang TY, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Mangla A, Barnholtz-Sloan J, Lee RT. Opneja A, et al. Among authors: mohamed a. Cancer Med. 2021 Jul;10(13):4397-4404. doi: 10.1002/cam4.3985. Epub 2021 May 31. Cancer Med. 2021. PMID: 34060249 Free PMC article.
Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
Hue JJ, Dorth J, Sugumar K, Hardacre JM, Ammori JB, Rothermel LD, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Hue JJ, et al. Among authors: mohamed a. Am Surg. 2021 Sep;87(9):1386-1395. doi: 10.1177/00031348211038581. Epub 2021 Aug 12. Am Surg. 2021. PMID: 34382877
Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma.
Sugumar K, Hue JJ, Hardacre JM, Ammori JB, Rothermel LD, Dorth J, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Sugumar K, et al. Among authors: mohamed a. HPB (Oxford). 2022 Apr;24(4):433-442. doi: 10.1016/j.hpb.2021.08.938. Epub 2021 Aug 18. HPB (Oxford). 2022. PMID: 34465529 Free article.
A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.
Elshami M, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge JE, Chavin KD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Elshami M, et al. Among authors: mohamed a. HPB (Oxford). 2022 Aug;24(8):1280-1290. doi: 10.1016/j.hpb.2021.12.022. Epub 2022 Jan 6. HPB (Oxford). 2022. PMID: 35063353 Free article.
Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery.
Huang LF, Hong A, Cioffi G, Alahmadi A, Tang TY, Ocuin LM, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Webb Hooper M, Barnholtz-Sloan J, Lee RT. Huang LF, et al. Among authors: mohamed a. Front Oncol. 2022 Feb 22;12:771688. doi: 10.3389/fonc.2022.771688. eCollection 2022. Front Oncol. 2022. PMID: 35273909 Free PMC article.
5,145 results